Alzheimer's Disease Market analysis and forecasts, 2007-2012, 2017 & 2022

Table of Contents

Chapter 1. Executive Summary

Chapter 2. An Introduction to Alzheimer' s Disease

• 2.1 Introduction
• 2.2 Symptoms and Differential Diagnosis
• 2.3 The Risk Factors for AD
• 2.4 Type of Protein as a Cause for AD?
  • 2.4.1 Neuronal and Synaptic Loss of AD
  • 2.4.2 Chromosomal Mutations of AD
  • 2.4.3 Inflammation of AD
  • 2.4.4 Using brain scans to detect Alzheimer' s
• 2.5 The Demographics for AD
• 2.6 Financial Burden of AD

Chapter 3. Pharmacotherapy for Alzheimer' s Disease

• 3.1 Current AD Pharmaceutical Drug Therapies
• 3.2 Acetylcholinesterase Drugs - How do you Treat Mild to Moderate AD?
  • 3.2.1 Pfizer/Eisai Aricept (Donepezil hyrdochloride) - The leading drug choice for AD
  • 3.2.1 Aricept clinical data
    • 3.2.1.1 Pre-clinical data
    • 3.2.1.2 Aricept clinical data outcomes
    • 3.2.1.3 Eisai and Pfizer Aricept post marketing research for AD
    • 3.2.1.4 Eisai severe Alzheimer' s disease trials
• 3.3 Novartis Excelon (Rivastigamine) - Popular Drug Therapy for AD
  • 3.3.1 Excelon mild-to-moderately severe Alzheimer' s disease clinical data
  • 3.3.2 J&J/ Shire Razadyne (Galantamine) is a Mild-to-moderate Treatment for AD
  • 3.3.3 J&J/ Shire Reminyl (Galantamine) clinical studies
  • 3.3.4 Forest and Lundbeck (Namenda/Ebixa) The Drug Treatments for Moderate to Severe AD
    • 3.3.4.1 Lundbeck Ebixa (Namenda) severe Alzheimer' s disease clinical data
    • 3.3.4.2 Lundbeck Ebixa (Namenda) mild-to-moderate Alzheimer' s disease clinical data
  • 3.3.5 Comparative efficacy of Clinical Approved AD drugs
  • 3.3.6 Cognex (Tacrine)
  • 3.3.7 Non steroidal anti-inflammatory drugs (NSAIDs)
• 3.4 Comorbid Conditions
• 3.5 Depression associated with Alzheimer' s disease and its management

Chapter 4. UK Alzheimer' s Disease treatment guidelines

• 4.1 UK-National Institute for Clinical Excellence guidelines
• 4.2 NICE 2001 AD guideline
  • 4.2.1 NICE reversal to 2001 AD guidance
  • 4.2.2 Stakeholders' reaction to NICE 2001 AD guidelines reversal
  • 4.2.3 NICE 2006 AD Guidance Review- Aricept, Razadyne, Exelon and Memantine
  • 4.2.4 Judicial Review of NICE guideline 2007

Chapter 5. Global AD market

• 5.1 Overview of Global AD market and Geographical analysis
• 5.2 US Alzheimer' s disease market
• 5.3 US AD Market Drivers and Restraints
  • 5.3.1 Market Drivers
  • 5.3.2 Market Restraints
• 5.4 Japan Alzheimer' s disease Market
• 5.5 Japan Market Drivers and Restraints
  • 5.5.1 Market Drivers
  • 5.5.2 Market Restraints
• 5.6 France Alzheimer' s disease Market
• 5.7 France AD Market Drivers and Restraints
  • 5.7.1 Market Drivers
  • 5.7.2 Market Restraints
• 5.8 Germany Alzheimer' s disease Market
• 5.9 Germany AD Market Drivers and Restraints
  • 5.9.1 Market Drivers
  • 5.9.2 Market Restraints
• 5.10 UK Alzheimer' s disease Market
• 5.11 UK AD Market Drivers and Restraints
  • 5.11.1 Market Drivers
  • 5.11.2 Market Restraints
• 5.12 Italy' s Alzheimer' s disease Market
• 5.13 Italy AD Market Drivers and Restraints
  • 5.13.1 Market Drivers
  • 5.13.2 Market Restraints
• 5.14 Spain' s Alzheimer' s disease Market
• 5.15 Spain AD Market Drivers and Restraints
  • 5.15.1 Market Drivers
  • 5.15.2 Market Restraints

Chapter 6. Key players in Alzheimer' s Disease Pharmacotherapy

• 6.1 Eisai/Pfizer' s Aricept
  • 6.1.1 Eisai Aricept product expansion
  • 6.1.2 Eisai R&D
• 6.2 Forest Laboratories Namenda /Lundbeck Ebixa product expansion
• 6.3 Shire Razadyne product expansion
• 6.4 Novartis Exelon product expansion
  • 6.4.1 Novartis Exelon TransdermalPatch for AD
  • 6.4.2 Potential Success of Exelon Transdermal Patch
  • 6.4.3 Novartis' Exelon and Forest Namenda combinatorial study
• 6.5 Will there be generic competition?
• 6.6 Market growth indications

Chapter 7. Alzheimer' s disease R&D and pipeline

• 7.1 Unmet medical needs for Alzheimer' s disease
• 7.2 Present clinical approaches to delivering AD therapies
  • 7.2.1 Biomarkers a prospective diagnostic tool
• 7.3 Overview of pipeline products
  • 7.3.1 Pipeline Drugs for AD
  • 7.3.2 Neurochem' s Alzhemed (anti-amyloid compound) illuminates strong therapeutic potential
  • 7.3.3 Forest' s Neramexane potential follow-on product for Namenda
  • 7.3.4. Other compounds presently in the pipeline
    • 7.3.4.1 PBT-1 (Coloquinol)
    • 7.3.4.2 Phenserine
    • 7.3.4.3 Allon Therapeutics' AL-108 and AL-208 to inhibit neuronal death
    • 7.3.4.4 Martek' s DHA reduces brain lesions in AD animal models
    • 7.3.4.5 Phytopharm Cogane -an orally active neuroprotective compound
    • 7.3.4.6 Nicotine Replacement Therapy as a Potential Treatment for AD
• 7.4 Emerging Therapies for Alzheimer' s disease
  • 7.4.1 Vitamin E (Antioxidants) for AD
  • 7.4.2 Research has revealed that Vitamin E, Vitamin C and other health foods possess oxidative properties.
  • 7.4.3 OTC Ginko Biloba May Slow AD Symptoms
  • 7.4.4 Oestrogen HRT May Protect Against AD

Chapter 8. Conclusions

• 8.1 Expansion of Global Population
• 8.2 Prevalence of Alzheimer' s disease in the Major Markets
• 8.3 FDA Approved Alzheimer' s disease Therapies and NICE' s Cost-Effective Analysis
• 8.4 Alzheimer' s disease Drug Sales across Major Markets 2006
• 8.5 Barriers to Generic entrants
• 8.6 Alzheimer' s disease Revenue ($m) Forecast
• 8.7 Leading Companies with Products in late-stage Alzheimer' s disease Pipeline

• Table 1.1 Prevalence of AD Accross The Seven Major Markets (2006)
• Table 1.2 AD Revenue Forecast ($m) for Seven Major Markets,2007-2012,2017 & 2022
• Table 1.3 SWOT Analysis on Alzheimer' s disease market
• Table 2.1 Prevalence of AD 2006-2050 In Three Geographical Regions
• Table 3.1 Assessment Scale for Defining Magnitude of AD
• Table 3.1 contn' d Assessment Scale for defining magnitude of AD
• Table 3.2 Summary of AD drugs clinical data
• Table 3.3 SSRIs Considered in Managing Depression in AD
• Table 3.4 Atypical antipsychotic agents considered in managing depression in AD
• Table 3.5 Typical antipsychotic agents considered in managing depression in AD
• Table 3.6 Anxiolytic Drugs Benzodiazepines Considered in Managing Depression in AD
• Table 3.7 Mood-Stabilizing (anti-agitation) Drugs Considered in Managing Depression in AD
• Table 5.1 The Global AD Market, 2004-2006
• Table 5.2 Sales for AD Therapies in the US, 2003-2006
• Table 5.3 US AD Sales Revenue Forecast ($m), 2007-2012, 2017 & 2022
• Table 5.4 J apan AD Sales Revenue Forecast ($m), 2007-2012, 2017 & 2022
• Table 5.5 Sales Revenues of AD Agents in France, 2003-2006
• Table 5.6 France AD Sales Revenue Forecast ($m), 2007-2012, 2017 & 2022
• Table 5.7 Sales Revenues for AD Therapies in Germany, 2003-2006
• Table 5.8 Germany AD Sales Revenue Forecast ($m), 2007-2012, 2017 & 2022
• Table 5.9 Sales Revenues for AD Therapies in the UK, 2003-2006
• Table 5.10 UK AD sales revenue forecast ($m), 2007-2012,2017 & 2022
• Table 5.11 Italy' s Sales Revenues for AD Therapies, 2003-2006
• Table 5.12 Italy AD Sales Revenue Forecast ($m), 2007-2012,2017 & 2022
• Table 5.13 Spain Sales Revenues for AD Therapies, 2003-2006
• Table 5.14 Spain AD Sales Revenue Forecast ($m), 2007-2012, 2017 & 2022
• Table 6.1 Summary of Aricepts Approved indications for AD
• Table 6.2 Present Aricept Extra indications in Major Markets
• Table 6.3 Patent Expiration on leading AD products in Major Markets
• Table 7.1 Alzheimer' s disease phase III Pipeline
• Table 7.2 Alzheimer' s disease phase II Pipeline
• Table 7.3 Alzheimer' s disease phase I Pipeline

List of Charts

• Chart 1.1 Demographics of Alzheimer' s Disease Across Major Markets, 2006
• Chart 1.2 Aricept Total Sales Revenue Across Seven Major Markets, 2006
• Chart 1.3 Memantine Total Sales Revenue Across Six Major Markets, 2006
• Chart 1.4 Razadyne (previously Reminyl) Total Sales Revenue Across Six Major Markets, 2006
• Chart 1.5 Exelon Total Sales Revenue Across Six Major Markets, 2006
• Chart 2.1 Current and Projected Global Prevalence of Alzheimer' s Disease
• Chart 2.2 Global Cost of AD During 2003-2005 ($bn)
• Chart 5.1 The Global Sales ($m) of AD drugs, 2004-2006
• Chart 5.2 The Global Market Share for Leading AD Drugs, 2006
• Chart 5.3 Sales for AD Therapies in the US, 2003-2006
• Chart 5.4 Market Share for AD agents in the US, 2006
• Chart 5.5 US AD Sales Revenue Forecast ($m), 2007-2012, 2017 & 2022
• Chart 5.6 Aricept Sales Revenue,2003-2006
• Chart 5.7 Japan AD Sales Revenue Forecast ($m), 2007-2012, 2017 & 2022
• Chart 5.8 Sale Revenues of AD Agents in France, 2003-2006
• Chart 5.9 Market Share for AD Agents in France,2006
• Chart 5.10 France AD Sales revenue Forecast ($m), 2007-2012, 2017 & 2022
• Chart 5.11 Sales Revenues for AD Therapies in Germany, 2003-2006
• Chart 5.12 Market Share for AD Agents in Germany,2006
• Chart 5.13 Germany AD Sales Revenue Forecast ($m), 2007-2012,2017 & 2022
• Chart 5.14 Sales Revenues for AD Therapies in the UK, 2003-2006
• Chart 5.15 Market Share for AD Agents in the UK, 2006
• Chart 5.16 UK AD Sales Revenue Forecast ($m), 2007-2012,2017 & 2022
• Chart 5.17 Sales Revenues for AD Therapies in Italy, 2003-2006
• Chart 5.18 Market Share for AD Agents in Italy,2006
• Chart 5.19 Italy AD Sales Revenue Forecast ($m), 2007-2012, 2017 & 2022
• Chart 5.20 Market Share for AD Agents in Spain, 2006
• Chart 5.21 Market Share for AD Agents in Spain, 2006
• Chart 5.22 Spain AD Sales Revenue Forecast ($m), 2007-2012, 2017 & 2022

COmpanies mentioned in this report include:

• Abbott
• Acambis
• Accera
• Aeolus
• Affiris
• Allon Therapeutics
• Antigenics
• AstraZeneca
• Athenagen
• Avera
• Barr Pharmaceuticals
• Bayer
• BTG
• CAD
• Cell Genesys
• Ceregene
• Chiesi
• CoMentis
• Cortex
• Cytos
• Dae Wong
• Daiichi Sankyo
• Debiopharm
• DebioPharma
• Ebewe' s
• Eisai
• Elan
• Eli Lilly
• Encore
• Enkam
• Epix Pharma
• Evotec
• First Horizon
• Florida University
• Forest
• GelTex
• Genzyme
• Helicon Inflazyme
• Hunter-Fleming
• Inflazyme
• Intellect Neuroscience
• J&J
• Janssen
• Loyola Medical School
• Lundbeck
• Martek
• Memory
• Merck Serono
• Merz
• Migenix
• Myriad
• Neurochem
• Neuro-Hitech
• Neuropharma
• Newron
• New York University
• NicOx
• Nippon Kayaku
• Novartis
• Nymox
• Ono
• Otsuka
• Pfizer
• Pharmexa
• Pierre Fabre
• Prana Technology
• Procter and Gamble
• Progenics
• Roche
• Sagittarius
• Sanofi Pasteur
• Sanofi-Aventis
• Shanghai Institute
• Shire
• Sloan Kettering
• Synaptech
• Taiho
• Teva
• The Stanley Medical
• Torrey Pines Therapeutics
• Toyama
• Transition
• UCB
• UK- National Institute of Clinical Excellence (NICE)
• University of Califonia
• University of South Alabama
• US Department of Health
• Vasogen
• Vernalis
• Wyeth